Solaris Endovascular Inc. — SEC Form D Filing

Solaris Endovascular Inc. filed an SEC Form D on October 1, 2026, reporting $4.97M raised in Medical Devices.

Form D filing details

Filing
SEC Form D
Filing date
October 1, 2026
Amount reported
$4.97M
Industry
Medical Devices
Website
https://www.solarisendovascular.com/

What the company does

Securities: Equity, Debt. Exemption: Rule 506(b). Incorporated: DELAWARE

Problem

Patients undergoing hemodialysis for End-Stage Kidney Disease (ESKD) frequently experience vascular access failures, leading to repeated, costly interventions and a reduced quality of life. Additionally, Peripheral Artery Disease (PAD) is a progressive condition where plaque buildup restricts blood flow to the legs and feet, impacting millions worldwide.

Solution

Solaris Endovascular develops advanced endovascular solutions, specifically next-generation electrospinning PTFE covered stent grafts, some of which feature innovative drug-eluting technology, to extend the patency of dialysis access grafts, fistulas, and peripheral arteries.

Verdict

Investors funded this because the solution addressed critical, well-understood clinical pain points in established medical device markets with a proven technology type. This cleared because of the incremental, applied innovation within a highly regulated but predictable sector, not because it promised disruptive market creation or a novel care paradigm. The implicit bet was on regulatory approval and adoption within existing hospital and clinic workflows, accepting that sales cycles would be long and pricing would be constrained by reimbursement codes, limiting aggressive growth multiples seen in software or unproven biotech.

Source: SEC EDGAR Form D filing